SPY326.52+2.56 0.79%
DIA264.35+1.07 0.41%
IXIC10,745.28+157.46 1.49%
News
DMPI
--
0.00%
--
LYG, BBVA among premarket losers
Seeking Alpha · 4d ago
Ocugen and vTv Therapeutics among healthcare gainers; Vaxart leads the losers
Seeking Alpha · 6d ago
Denovo Biopharma's enzastaurin Fast Track'd for brain tumor
The FDA designates privately held Denovo Biopharma's lead candidate DB102 (enzastaurin) for Fast Track review for the treatment of newly diagnosed glioblas
seekingalpha · 07/17 17:18
DelMar Pharmaceuticals to Host Conference Call to Discuss Proposed Acquisition of Adgero Pharmaceuticals
DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies announced today that it will be conducting a conference call to discuss the Company's previously
PR Newswire · 07/17 12:00
DelMar Pharma receives loan for trial and study
Seeking Alpha - Article · 06/24 13:57
DelMar Pharma secures $500K loan to support advancement of VAL-083
Seeking Alpha - Article · 06/24 13:57
DelMar Pharmaceuticals Receives $500,000 Loan from the National Brain Tumor Society and National Foundation for Cancer Research to Support VAL-083's Participation in a Pivotal Study for Glioblastoma Sponsored by the Global Coalition for Adaptive Research
PR Newswire · 06/24 13:30
DelMar Pharma Receives $500K Loan From National Brain Tumor Society, National Foundation For Cancer Research To Support VAL-083s Participation In Pivotal Study For Glioblastoma
Benzinga · 06/24 12:34
DelMar Pharma down 17% on underwhelming VAL-083 data
Seeking Alpha - Article · 06/22 16:35
DelMar Pharmaceuticals Presents Interim Data On VAL-083 Demonstrating Favorable Outcomes In Both Newly- Diagnosed And Recurrent GBM At AACR Annual Meeting II
SAN DIEGO, June 22, 2020 /PRNewswire/ --DelMar Pharmaceuticals, Inc.(NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor
Benzinga · 06/22 12:36
DelMar Pharmaceuticals Presents Positive Interim Data on VAL-083 Demonstrating Favorable Outcomes in Both Newly- Diagnosed and Recurrent GBM at the AACR Virtual Annual Meeting II
DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced positive interim data from its two Phase 2 trials of VAL-083 for the treatment
PR Newswire · 06/22 12:30
The Week Ahead In Biotech: Karyopharm, Zogenix, Heron, Chiasma On The Radar Ahead Of FDA Decisions
Biotech stocks rebounded along with the broader market in the week ended June 19.
Benzinga · 06/21 18:53
NCLH, DKNG among premarket losers
Seeking Alpha - Article · 06/17 12:18
DelMar to Acquire Adgero Biopharmaceuticals, Expands Late-Stage Oncology Pipeline
PR Newswire · 06/10 13:30
DelMar Pharma rallies on acquisition of Adgero Bio
Seeking Alpha - Article · 06/10 13:07
DelMar Pharma Reports Purchase Of Adgero Bipharma, No Terms Disclosed
DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar") and Adgero Biopharmaceuticals Holdings, Inc. ("Adgero") today announced the companies have entered into a definitive merger agreement
Benzinga · 06/10 12:50
Global Coalition for Adaptive Research (GCAR) Selects DelMar Pharmaceuticals' VAL-083 to Participate in the GBM AGILE Pivotal Study, an Adaptive Clinical Trial Platform in Glioblastoma Multiforme
PR Newswire · 06/04 13:00
Global Coalition For Adaptive Research (GCAR) Selects DelMar Pharmaceuticals' VAL-083 To Participate In GBM AGILE Pivotal Study, An Adaptive Clinical Trial Platform In Glioblastoma Multiforme
SAN DIEGO, June 4, 2020 /PRNewswire/ --DelMar Pharmaceuticals, Inc.(NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer
Benzinga · 06/04 12:03
DelMar Pharmaceuticals to Present Updates of Two Phase 2 Clinical Trials of VAL-083 at the 2020 American Association for Cancer Research Virtual Annual Meeting II
PR Newswire · 06/01 13:00
The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 28)
Benzinga · 05/29 11:22